Full-Time
Associate Director/Director Business Development
Genomics
51-200 employees
Drives genomics-powered health insights and partnerships
No salary listed
Research Triangle Park, Durham, NC, USA + 3 more
More locations: Raleigh, NC, USA | Durham, NC, USA | Chapel Hill, NC, USA
Hybrid
Hybrid role based out of the Research Triangle Park office; the role covers the West Coast market.
Bachelor's, Master's
 Business & Strategy (1) |
|---|
Get referred to Genomics
See people who can refer or advise you
- A substantial track record of senior-level Software as a Service, digital health, or enterprise technology sales into pharmaceutical or biotechnology companies, with demonstrable success closing complex, high-value deals.
- Deep experience engaging with research and development and research departments inside major pharmaceutical companies and navigating senior scientific and commercial stakeholders.
- Strong working knowledge of genetics or genomics sufficient to discuss advanced genetic analytics credibly in the context of drug discovery.
- Strategic thinking about markets, clients, and positioning.
- Experience operating as a self-directed senior operator in a fast-paced scale-up environment.
- A degree in life sciences, business, or a related field is expected.
- Own and drive significant new commercial opportunities across pharmaceutical and biotechnology companies by building multi-stakeholder relationships at senior and executive levels and leading complex, high-value sales cycles from first conversation to contract close.
- Develop executive client relationships by understanding clients' long-term research and development and data strategies and positioning Mystra as a scientific partner.
- Provide market leadership by bringing a sophisticated view of the life sciences landscape, feeding strategic intelligence into the go-to-market approach, and influencing platform positioning and evolution.
- Set a high standard for pipeline discipline and forecasting and contribute to strategic reporting that informs senior decision-making.
- Act as the voice of the customer internally by shaping how Product, Science, and Marketing understand the market and ensuring the commercial approach is grounded in customer value.
- An advanced degree is a genuine asset.
Genomics plc uses genomic data to improve health care and drug discovery. It analyzes patients' genetic information to generate insights about biology and disease and then integrates these findings into clinical practice and research. The company partners with healthcare systems, pharmaceutical companies, providers, and payers to apply genomics to personalized medicine, helping doctors select better treatments and accelerating the development of new drugs. Its offerings include data-driven analytics and decision-support that embed genomic information into clinical and research workflows. Genomics plc differentiates itself by pursuing wide-ranging collaborations across the healthcare ecosystem to turn genomic data into practical, real-world decisions. The goal is to enable longer, healthier lives by making care and therapy choices more precise through genomics.
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$136M
Headquarters
Oxford, United Kingdom
Founded
2014
Get referred to Genomics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Genomics opened its London flagship office on February 25, 2026, signaling expansion.
- Mystra AI entered early-access use with major pharma on June 2, 2026.
- Greywolf's April 30, 2026 autoimmune collaboration expands Genomics into new therapeutic areas.
What critics are saying
- Vertex's collaboration runs only until 2026, exposing Genomics to contract-renewal risk.
- Genomics depends on a small set of pharma partnerships, creating concentration risk.
- If pharma stops paying for genetics-driven target selection, Genomics loses its core business.
What makes Genomics unique
- Genomics' Mystra AI, launched June 2, 2026, combines human genetics and conversational AI.
- Its database spans 45,000 GWAS and trillions of rows, a scale rivals lack.
- Vertex, Novo Nordisk, and Greywolf already use Genomics' genetics to guide pipelines.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Pension scheme
Flexible Working?
Hybrid Work Options
Holiday: 25 days annual leave, plus bank holidays, plus an extra 3-day company-wide shutdown at year-end
Wellness Program
Mental Health Support
Family Planning Benefits
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 3%2 year growth
↑ 1%Genomics has launched Mystra AI, a conversational AI platform for drug target discovery and validation, now adopted by pharmaceutical giants including Novo Nordisk and biotechs like BridgeBio Pharma and Relation Therapeutics. The platform leverages Genomics' proprietary database containing over 45,000 genome-wide association studies and trillions of data rows—the world's largest genotype-phenotype collection. With 95% of drug candidates failing in clinical trials, Mystra AI addresses this by focusing on genetically-supported targets, which are 2.6 times more likely to succeed. Mystra AI allows scientists to query the database using plain language, providing transparent, verifiable genetic insights for target discovery and validation. The platform offers three engagement models: self-service access, partly managed for proprietary data integration, and fully managed collaboration with Genomics' team of over 60 statistical geneticists.
Greywolf and Genomics partner to develop first-in-class ERAP autoimmune disease treatments. April 30, 2026 UK-based Greywolf Therapeutics and Genomics have announced a strategic research collaboration to apply large-scale human genetic data to the development of ERAP autoimmune disease treatments, with Genomics deploying its proprietary genotype-phenotype platform to validate ERAP1 and ERAP2 as therapeutic targets across multiple autoimmune indications and guide Greywolf's pipeline expansion strategy. Under the agreement, Genomics will curate and analyze multiple independent genetic association studies drawn from what the company describes as the world's largest harmonized genotype-phenotype data resource, with the objective of identifying which specific ERAP1 ERAP2 genetic variants drive disease susceptibility across conditions including inflammatory bowel disease, ankylosing spondylitis, and psoriasis. The resulting insights will inform Greywolf's indication selection and patient stratification strategy for its ERAP-targeting small molecule pipeline, with GRWD0715 currently progressing in a Phase I/II trial in axial spondyloarthritis. Financial terms were not disclosed. Greywolf's development program centers on antigen modulation - specifically the control of T cell activation through modulation of antigen presentation via the MHC class I pathway. ERAP1 and ERAP2 are aminopeptidases responsible for trimming peptides prior to loading onto MHC class I molecules; genetic variants in both enzymes alter the antigenic peptide repertoire presented to the immune system, and have been shown through genome-wide association studies to increase susceptibility to a range of autoimmune conditions. Greywolf's first-in-class autoimmune treatment approach targets this mechanism directly, with GRWD0715 designed to correct aberrant antigen presentation rather than broadly suppress immune function. The collaboration addresses a specific technical challenge in ERAP-focused immunotherapy drug development: ERAP1 and ERAP2 are highly polymorphic, with multiple functionally distinct haplotypes that produce different enzymatic activities across human populations. Standard preclinical models cannot capture this complexity, making human genetic evidence the most reliable basis for both target validation and indication prioritization. Genomics' platform applies statistical genetics methods including Mendelian randomization and colocalization analysis to biobank-scale datasets, enabling causal inference at the variant level rather than relying on aggregate association signals. Genomics, spun out of the University of Oxford in 2014, has built its platform over a decade of statistical and human genetics research. The company's CEO and co-founder, Professor Sir Peter Donnelly, previously directed the Wellcome Centre for Human Genetics at Oxford, where his group conducted genome-wide association studies that identified ERAP1 and ERAP2 as autoimmune disease risk genes. That scientific history positions Genomics as a particularly direct fit for this program, given that the foundational genetic evidence underpinning Greywolf's target selection originated in part from the same institution. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked *
Genomics and greywolf partner in autoimmune diseases. April 30, 2026 Genomics Ltd. has established a strategic relationship with Grey Wolf Therapeutics Ltd. (Greywolf) to develop first-in-class treatments for autoimmune diseases.
Genomics Ltd., BioMarin Pharmaceutical partner on rare disease research. NEW YORK - Genomics Ltd. on Thursday announced an ongoing partnership with BioMarin Pharmaceutical to advance rare disease drug discovery and development. To read the full story...
Genomics launches Mystra: the world's first and original AI-enabled human genetics platform, now available to transform drug target discovery and clinical development. The Mystra platform, developed over 10 years, offers biopharma partners proven analytical power to turn months of R&D into minutes, dramatically increasing the availability of quality genetic insights and, therefore, the probability of honing in on successful drug candidates BOSTON, Oct. 16, 2025 /PRNewswire/ - Genomics, a science-led techbio company using large-scale genetic information to develop innovative precision healthcare tools and to accelerate drug discovery and development, has today announced the launch of Mystra, the world's original AI-enabled human genetics platform designed to supercharge drug target discovery and validation. The platform was officially announced during a Genomics presentation at the American Society of Human Genetics 2025 in Boston. The pharmaceutical industry faces a significant research and development (R&D) productivity crisis, with the failure rate for drug candidates in clinical trials soaring to 95%. This rate pushes the average cost of bringing a new medicine to market beyond $2.3 billion, leading to unsustainable pricing and restricted patient access to life-saving treatments. Genomics is addressing this challenge by equipping researchers with a powerful solution built on the fact that targets with human genetic support are 2.6 times more likely to succeed in clinical trials. Over the last 10 years, Genomics has ingested, harmonized, and quality-controlled what is now the world's largest and most diverse human genotype-phenotype database. The new platform builds on and augments these datasets, providing extensive, powerful insights into human biology, with relevant information for drug development and critical insights into disease mechanisms supported by evidence from studies of genetic variation. Enabled by proprietary AI and advanced algorithms, Genomics' Foundational Data Collection encompasses over 20,000 genome-wide associated studies (GWAS) and trillions of rows of data. Mystra harnesses world-leading algorithms, providing users with critical insights into disease mechanisms supported by evidence from studies of genetic variation. Augmented with cutting-edge machine learning tools, this platform delivers rapid, deep analyses necessary for drug development. Human genetics teams currently spend excessive time managing fragmented, siloed datasets and running manual analyses. Insights are often generated too late to meaningfully influence early discovery or clinical strategy. Collaboration across biology, chemistry, and clinical teams is slow as data and tools are not integrated. This can now change with Mystra. Mystra turns human genetics from a slow, fragmented, specialist-driven process into a high-speed, integrated capability that informs drug discovery and development. By unifying genomic data, analysis tools, and collaboration capabilities in one platform, it makes genetics teams dramatically more productive - so they can spend time on insight generation, not data cleanup. It enables earlier, stronger decision-making in target identification, validation, and clinical trial design, and it connects cross-functional teams with a shared source of truth for genetic evidence. Mystra is the culmination of a decade-long effort, providing a secure, scalable, and intuitive platform that allows users to: * Build Genetic Conviction: Instantly assess the efficacy and safety of drug candidates against the world's most comprehensive human genetic evidence. * Accelerate R&D: Turn complex genetic analysis queries that historically took months into results in a matter of minutes. * De-Risk Investment: Increase the probability of success for every drug candidate by helping choose better drug candidates, resulting in higher-quality assets entering the pipeline. Genomics' own use of the platform is expected to contribute dozens of targets to pharma R&D pipelines this year alone. "For over a decade, we have been meticulously building and using an unparalleled platform of genetic insights to accelerate our own collaborations with biopharma partners," said Dave Thornton, President, Genomics. "Today, we are making this breakthrough technology available to the statistical geneticists throughout the R&D community. Mystra transforms fragmented data into actionable, high-conviction insights, empowering statistical geneticists and life sciences companies to make real-time decisions that were previously impossible. We are changing the trajectory of drug development - to bring tomorrow's medicine for the patients of today, safer and faster." The platform will be the first ever fully scalable solution available to life sciences companies for the use of multi-omic data for R&D. Omics data is heterogeneous and requires specialist expertise and complex methods to harmonize, analyze, and extract meaningful and actionable insights. Pharmaceutical and biotech partners can access Mystra's unmatched scale and analytical power through flexible engagement models: * Self-service (SaaS): Enroll teams for direct access to Mystra, leveraging the platform's proprietary datasets and analysis tools. * Partly Managed: Bring proprietary internal data to securely combine it with Genomics' world-leading datasets for bespoke analysis. * Fully Managed: Collaborate with Genomics' team of over 60 statistical genetic scientists - one of the largest in Europe - to supercharge pipelines and accelerate breakthroughs. Mystra is already being used by several of the world's largest pharmaceutical companies in an early-access program. Looking ahead, it will continue to expand its multi-modal capabilities, ensuring it becomes an integral platform empowering every scientist across the discovery and development journey. For more information and to explore the platform, visit mystra.com. For more information about Genomics, visit genomics.com. About Genomics Genomics is a pioneering science-led techbio company that uses large-scale genetic information to develop innovative precision healthcare tools and bring new understanding to drug discovery. Valley Times-News were formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford. Today, Valley Times-News is collaborating with some of the world's leading healthcare organisations and helping them to predict, prevent, treat, and cure - dramatically reducing the human and financial cost of common diseases like cancer, diabetes, and heart disease. View original content to download multimedia:https://www.prnewswire.com/news-releases/genomics-launches-mystra-the-worlds-first-and-original-ai-enabled-human-genetics-platform-now-available-to-transform-drug-target-discovery-and-clinical-development-302586011.html SOURCE Genomics